Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution used as a laxative for bowel cleansing.
## Primary Indications
* Bowel preparation for diagnostic procedures (e.g., colonoscopy, sigmoidoscopy).
* Relief of occasional constipation.
## Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 fl oz (133 mL) unit is administered. For optimal cleansing, doses may be given in split-dosing regimens (e.g., half the evening before and half the morning of the procedure), as per institutional protocol.
* **Constipation:** One 2.25 fl oz (66 mL) unit.
## Pediatric Dosing
* **Age 2-5 years:** 1/2 of the 2.25 fl oz (66 mL) unit (approximately 1.125 fl oz or 33 mL).
* **Age 6-11 years:** 1.125 fl oz to 2.25 fl oz (33 mL to 66 mL), depending on clinical response and institutional guidelines.
* **Age 12 years and older:** Same as adult dosing.
*Note: Use in children under 2 years of age is generally not recommended due to increased risk of toxicity.*
## Dose Adjustments
* Use with caution in patients with impaired renal function, heart failure, or existing electrolyte imbalances. Specific dose adjustments are not typically defined, but reduced frequency or alternative agents may be considered.
## Contraindications
* Congenital megacolon.
* Congestive heart failure.
* Intestinal obstruction or perforation.
* Severe dehydration.
* Children under 2 years of age.
* Patients with impaired renal function or those on medications that affect renal function.
* Patients with a condition that increases the risk of electrolyte disturbances or fluid imbalance.
## Adverse Effects
* **Common:** Abdominal cramping, bloating, nausea, vomiting, diarrhea.
* **Serious:** Hyperphosphatemia, hypocalcemia, hypokalemia, hypernatremia, hyponatremia, metabolic acidosis, dehydration, renal tubular damage, seizures, cardiac arrhythmias. Severe cases can lead to rhabdomyolysis or death.
## Key Drug Interactions
* **Diuretics:** Increased risk of electrolyte disturbances.
* **ACE inhibitors and ARBs:** May increase the risk of hyperkalemia, especially in patients with renal impairment.
* **NSAIDs:** May increase the risk of renal impairment.
* **Drugs affecting bowel motility:** May alter the efficacy or safety of the enema.
## Monitoring
* Electrolytes (phosphate, calcium, potassium, sodium) before and after administration, especially in at-risk populations.
* Renal function (BUN, creatinine).
* Signs and symptoms of dehydration.
## Clinical Pearls
* Rapid administration can increase cramping and discomfort.
* Ensure adequate fluid intake before and after administration to prevent dehydration.
* This product should not be used for more than one consecutive day without medical advice due to the risk of serious electrolyte disturbances.
* Strict adherence to recommended dosage and administration instructions is crucial to minimize risk.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most up-to-date and comprehensive details.*
